Myc proteins in brain tumor development and maintenance

References

• Eilers M, Eisenman RN. Myc's broad reach. Genes Dev. 2008;22:2755–66.
   PubMed Web of Science ®Google Scholar
• Stanton BR, Perkins AS, Tessarollo L, Sassoon DA, Parada LF. Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop. Genes Dev. 1992;6:2235–47.
   PubMed Web of Science ®Google Scholar
• Charron J, Malynn BA, Fisher P, Stewart V, Jeannotte L, Goff SP, Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene. Genes Dev. 1992;6:2248–57.
   PubMed Web of Science ®Google Scholar
• Davis AC, Wims M, Spotts GD, Hann SR, Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev. 1993;7:671–82.
   PubMed Web of Science ®Google Scholar
• Knoepfler PS, Cheng PF, Eisenman RN. N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev. 2002;16:2699–712.
   PubMed Web of Science ®Google Scholar
• Hatton BA, Knoepfler PS, Kenney AM, Rowitch DH, de Alboran IM, Olson JM, N-myc is an essential downstream effector of Shh signaling during both normal and neoplastic cerebellar growth. Cancer Res. 2006;66:8655–61.
   PubMed Web of Science ®Google Scholar
• Zindy F, Knoepfler PS, Xie S, Sherr CJ, Eisenman RN, Roussel MF. N-Myc and the cyclin-dependent kinase inhibitors p18Ink4c and p27Kip1 coordinately regulate cerebellar development. Proc Natl Acad Sci USA. 2006;103:11579–83.
   PubMed Web of Science ®Google Scholar
• Wey A, Knoepfler PS. c-myc and N-myc promote active stem cell metabolism and cycling as architects of the developing brain. Oncotarget. 2010;1:120–30.
   PubMedGoogle Scholar
• Fults D, Pedone C, Dai C, Holland EC. MYC expression promotes the proliferation of neural progenitor cells in culture and in vivo. Neoplasia. 2002;4:32–9.
   PubMedGoogle Scholar
• Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol. 2004;63:441–9.
   PubMed Web of Science ®Google Scholar
• Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol. 2009;27:1627–36.
   PubMed Web of Science ®Google Scholar
• Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med. 2002;126:540–4.
   PubMed Web of Science ®Google Scholar
• Yang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourboulas M, Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells. Cancer Cell. 2008;14:135–45.
   PubMed Web of Science ®Google Scholar
• Brennan C, Momota H, Hambardzumyan D, Ozawa T, Tandon A, Pedraza A, Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One. 2009;4:e7752.
   PubMed Web of Science ®Google Scholar
• Perry A, Miller CR, Gujrati M, Scheithauer BW, Zambrano SC, Jost SC, Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol. 2009;19:81–90.
   PubMed Web of Science ®Google Scholar
• Rouah E, Wilson DR, Armstrong DL, Darlington GJ. N-myc amplification and neuronal differentiation in human primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1989;49:1797–801.
   PubMed Web of Science ®Google Scholar
• Browd SR, Kenney AM, Gottfried ON, Yoon JW, Walterhouse D, Pedone CA, N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma. Cancer Res. 2006;66:2666–72.
   PubMed Web of Science ®Google Scholar
• Kessler JD, Hasegawa H, Brun SN, Yang ZJ, Dutton JW, Wang F, N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma. Genes Dev. 2009;23:157–70.
   PubMedGoogle Scholar
• Zindy F, Uziel T, Ayrault O, Calabrese C, Valentine M, Rehg JE, Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors. Cancer Res. 2007;67:2676–84.
   PubMedGoogle Scholar
• Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Pleiotropic role for MYCN in medulloblastoma. Genes Dev. 2010;24:1059–72.
   PubMed Web of Science ®Google Scholar
• Momota H, Shih AH, Edgar MA, Holland EC. C-Myc and beta-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice. Oncogene. 2008;27:4392–401.
   PubMedGoogle Scholar
• Lassman AB, Dai C, Fuller GN, Vickers AJ, Holland EC. Overexpression of c-MYC promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt signaling to induce gliomas from GFAP-expressing cells in mice. Neuron Glia Biol. 2004;1:157–63.
   PubMedGoogle Scholar
• Lee JS, Lee HJ, Moon BH, Song SH, Lee MO, Shim SH, Generation of Cancerous neural stem cells forming glial tumor by oncogenic stimulation. Stem Cell Rev. 2011;Jul14 Epub ahead of print.
   Google Scholar
• Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8:976–90.
   PubMed Web of Science ®Google Scholar
• Davis FG, McCarthy BJ, Berger MS. Centralized databases available for describing primary brain tumor incidence, survival, and treatment: Central Brain Tumor Registry of the United States; Surveillance, Epidemiology, and End Results; and National Cancer Data Base. Neuro Oncol. 1999;1:205–11.
   PubMedGoogle Scholar
• Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol. 2004;5:209–18.
   PubMed Web of Science ®Google Scholar
• Eberhart CG, Burger PC. Anaplasia and grading in medulloblastomas. Brain Pathol. 2003;13:376–85.
   PubMed Web of Science ®Google Scholar
• Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24:1924–31.
   PubMed Web of Science ®Google Scholar
• Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008;3:e3088.
   PubMed Web of Science ®Google Scholar
• Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011;29:1424–30.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29:1408–14.
   PubMed Web of Science ®Google Scholar
• Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2011; [Epub ahead of print].
   Google Scholar
• Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, Straughton D, Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle. 2006;5:2666–70.
   PubMed Web of Science ®Google Scholar
• Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011;121:381–96.
   PubMed Web of Science ®Google Scholar
• Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Subtypes of medulloblastoma have distinct developmental origins. Nature. 2010;468:1095–9.
   PubMed Web of Science ®Google Scholar
• Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006;66:7445–52.
   PubMed Web of Science ®Google Scholar
• Fouladi M, Stewart CF, Olson J, Wagner LM, Onar-Thomas A, Kocak M, Phase I trial of MK-0752 in children with refractory CNS malignancies: A pediatric brain tumor consortium study. J Clin Oncol. 2011;29:3529–34.
   PubMed Web of Science ®Google Scholar
• Hatton BA, Villavicencio EH, Pritchard J, LeBlanc M, Hansen S, Ulrich M, Notch signaling is not essential in sonic hedgehog-activated medulloblastoma. Oncogene. 2010;29:3865–72.
   PubMedGoogle Scholar
• Julian E, Dave RK, Robson JP, Hallahan AR, Wainwright BJ. Canonical Notch signaling is not required for the growth of Hedgehog pathway-induced medulloblastoma. Oncogene. 2010;29:3465–76.
   PubMedGoogle Scholar
• Wu X, Northcott PA, Croul S, Taylor MD. Mouse models of medulloblastoma. Chin J Cancer. 2011;30:442–9.
   PubMedGoogle Scholar
• Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science. 1997;277:1109–13.
   PubMed Web of Science ®Google Scholar
• Eberhart CG, Kratz JE, Schuster A, Goldthwaite P, Cohen KJ, Perlman EJ, Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol. 2002;12:36–44.
   PubMed Web of Science ®Google Scholar
• Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. C-myc overexpression causes anaplasia in medulloblastoma. Cancer Res. 2006;66:673–81.
   PubMed Web of Science ®Google Scholar
• Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415:436–42.
   PubMed Web of Science ®Google Scholar
• Kenney AM, Cole MD, Rowitch DH. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development. 2003;130:15–28.
   PubMed Web of Science ®Google Scholar
• Korshunov A, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol. 2011; [Epub ahead of print].
   Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97–109.
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.
   PubMed Web of Science ®Google Scholar
• Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157–73.
   PubMed Web of Science ®Google Scholar
• TCGA research network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–8.
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.
   PubMed Web of Science ®Google Scholar
• Herms JW, von Loewenich FD, Behnke J, Markakis E, Kretzschmar HA. C-myc oncogene family expression in glioblastoma and survival. Surg Neurol. 1999;51:536–42.
   PubMedGoogle Scholar
• Hui AB, Lo KW, Yin XL, Poon WS, Ng HK. Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest. 2001;81:717–23.
   PubMed Web of Science ®Google Scholar
• Faria MH, Khayat AS, Burbano RR, Rabenhorst SH. C--MYC amplification and expression in astrocytic tumors. Acta Neuropathol. 2008;116:87–95.
   PubMedGoogle Scholar
• Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, Yu M, Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. Neuro Oncol. 2009;11:477–87.
   PubMed Web of Science ®Google Scholar
• Ho JS, Ma W, Mao DY, Benchimol S. p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol. 2005;25:7423–31.
   PubMed Web of Science ®Google Scholar
• Broaddus WC, Chen ZJ, Prabhu SS, Loudon WG, Gillies GT, Phillips LL, Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells. Neurosurgery. 1997;41:908–15.
   PubMedGoogle Scholar
• Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, c-Myc is required for maintenance of glioma cancer stem cells. PLoS One. 2008;3:e3769.
   PubMed Web of Science ®Google Scholar
• Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008;455:1129–33.
   PubMed Web of Science ®Google Scholar
• Amati B, Brooks MW, Levy N, Littlewood TD, Evan GI, Land H. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell. 1993;72:233–45.
   PubMed Web of Science ®Google Scholar
• Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN, Weintraub H. Sequence-specific DNA binding by the c-Myc protein. Science. 1990;250:1149–51.
   PubMed Web of Science ®Google Scholar
• Papoulas O, Williams NG, Kingston RE. DNA binding activities of c-Myc purified from eukaryotic cells. J Biol Chem. 1992;267:10470–80.
   PubMed Web of Science ®Google Scholar
• Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol. 2001;3:392–9.
   PubMed Web of Science ®Google Scholar
• Herold S, Herkert B, Eilers M. Facilitating replication under stress: an oncogenic function of MYC? Nat Rev Cancer. 2009;9:441–4.
   PubMed Web of Science ®Google Scholar
• Wu S, Cetinkaya C, Munoz-Alonso MJ, von der Lehr N, Bahram F, Beuger V, Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene. 2003;22:351–60.
   PubMed Web of Science ®Google Scholar
• Patel JH, Loboda AP, Showe MK, Showe LC, McMahon SB. Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer. 2004;4:562–8.
   PubMedGoogle Scholar
• Hatton KS, Mahon K, Chin L, Chiu FC, Lee HW, Peng D, Expression and activity of L-Myc in normal mouse development. Mol Cell Biol. 1996;16:1794–804.
   PubMed Web of Science ®Google Scholar
• Kenney AM, Widlund HR, Rowitch DH. Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development. 2004;131:217–28.
   PubMed Web of Science ®Google Scholar
• Sjostrom SK, Finn G, Hahn WC, Rowitch DH, Kenney AM. The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell. 2005;9:327–38.
   PubMed Web of Science ®Google Scholar
• Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M, c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell. 2006;21:509–19.
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2008;26:101–6.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–76.
   PubMed Web of Science ®Google Scholar
• Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008;451:141–6.
   PubMed Web of Science ®Google Scholar
• Kim SU, Park IH, Kim TH, Kim KS, Choi HB, Hong SH, Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease. Neuropathology. 2006;26:129–40.
   PubMedGoogle Scholar
• Villa A, Snyder EY, Vescovi A, Martinez-Serrano A. Establishment and properties of a growth factor-dependent, perpetual neural stem cell line from the human CNS. Exp Neurol. 2000;161:67–84.
   PubMed Web of Science ®Google Scholar
• Queva C, Hurlin PJ, Foley KP, Eisenman RN. Sequential expression of the MAD family of transcriptional repressors during differentiation and development. Oncogene. 1998;16:967–77.
   PubMedGoogle Scholar
• Schreiber-Agus N, DePinho RA. Repression by the Mad(Mxi1)-Sin3 complex. Bioessays. 1998;20:808–18.
   PubMedGoogle Scholar
• Wechsler DS, Shelly CA, Petroff CA, Dang CV. MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res. 1997;57:4905–12.
   PubMed Web of Science ®Google Scholar
• Manni I, Tunici P, Cirenei N, Albarosa R, Colombo BM, Roz L, Mxi1 inhibits the proliferation of U87 glioma cells through down-regulation of cyclin B1 gene expression. Br J Cancer. 2002;86:477–84.
   PubMedGoogle Scholar
• Hann SR, Eisenman RN. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol. 1984;4:2486–97.
   PubMed Web of Science ®Google Scholar
• Pulverer BJ, Fisher C, Vousden K, Littlewood T, Evan G, Woodgett JR. Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene. 1994;9:59–70.
   PubMed Web of Science ®Google Scholar
• Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14:2501–14.
   PubMed Web of Science ®Google Scholar
• Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3 controls c-myc proteolysis and subnuclear localization. J Biol Chem. 2003;278:51606–12.
   PubMed Web of Science ®Google Scholar
• Flinn EM, Busch CM, Wright AP. Myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome. Mol Cell Biol. 1998;18:5961–9.
   PubMedGoogle Scholar
• Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J. 1999;18:717–26.
   PubMed Web of Science ®Google Scholar
• Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6:308–18.
   PubMed Web of Science ®Google Scholar
• Schrader EK, Harstad KG, Matouschek A. Targeting proteins for degradation. Nat Chem Biol. 2009;5:815–22.
   PubMed Web of Science ®Google Scholar
• Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J. 2000;19:94–102.
   PubMed Web of Science ®Google Scholar
• Blancato J, Singh B, Liu A, Liao DJ, Dickson RB. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer. 2004;90:1612–19.
   PubMed Web of Science ®Google Scholar
• Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA. 2002;99:12963–8.
   PubMed Web of Science ®Google Scholar
• Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol. 2006;16:318–30.
   PubMed Web of Science ®Google Scholar
• Thomas LR, Tansey WP. Proteolytic control of the oncoprotein transcription factor Myc. Adv Cancer Res. 2011;110:77–106.
   PubMed Web of Science ®Google Scholar
• Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004;23:2116–25.
   PubMed Web of Science ®Google Scholar
• O'Neil J, Look AT. Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene. 2007;26:6838–49.
   PubMedGoogle Scholar
• Hoeck JD, Jandke A, Blake SM, Nye E, Spencer-Dene B, Brandner S, Fbw7 controls neural stem cell differentiation and progenitor apoptosis via Notch and c-Jun. Nat Neurosci. 2010;13:1365–72.
   PubMedGoogle Scholar
• Jandke A, Da Costa C, Sancho R, Nye E, Spencer-Dene B, Behrens A. The F-box protein Fbw7 is required for cerebellar development. Dev Biol. 2011;358:201–12.
   PubMedGoogle Scholar
• Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell. 2003;11:1177–88.
   PubMed Web of Science ®Google Scholar
• Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci USA. 2001;98:5043–8.
   PubMed Web of Science ®Google Scholar
• von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell. 2003;11:1189–200.
   PubMed Web of Science ®Google Scholar
• Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol. 2007;9:765–74.
   PubMed Web of Science ®Google Scholar
• Schwamborn JC, Berezikov E, Knoblich JA. The TRIM-NHL protein TRIM32 activates microRNAs and prevents self-renewal in mouse neural progenitors. Cell. 2009;136:913–25.
   PubMedGoogle Scholar
• Papas TS, Lautenberger JA. Sequence curiosity in v-myc oncogene. Nature. 1985;318:237.
   PubMedGoogle Scholar
• Hoang AT, Lutterbach B, Lewis BC, Yano T, Chou TY, Barrett JF, A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol. 1995;15:4031–42.
   PubMed Web of Science ®Google Scholar
• Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 2004;91:355–8.
   PubMed Web of Science ®Google Scholar
• Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 1983;304:596–602.
   PubMed Web of Science ®Google Scholar
• Foroni C, Galli R, Cipelletti B, Caumo A, Alberti S, Fiocco R, Resilience to transformation and inherent genetic and functional stability of adult neural stem cells ex vivo. Cancer Res. 2007;67:3725–33.
   PubMed Web of Science ®Google Scholar
• Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet. 2008;Chapter 10:Unit 10.11.
   PubMedGoogle Scholar
• Hydbring P, Bahram F, Su Y, Tronnersjo S, Hogstrand K, von der Lehr N, Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc Natl Acad Sci USA. 2010;107:58–63.
   PubMed Web of Science ®Google Scholar
• Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol. 2010;12:54–9; sup pp 1–14.
   PubMed Web of Science ®Google Scholar
• Johansson FK, Brodd J, Eklof C, Ferletta M, Hesselager G, Tiger CF, Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging. Proc Natl Acad Sci USA. 2004;101:11334–7.
   PubMed Web of Science ®Google Scholar
• Johansson Swartling F. Identifying candidate genes involved in brain tumor formation. Ups J Med Sci. 2008;113:1–38.
   PubMed Web of Science ®Google Scholar
• Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature. 2005;436:272–6.
   PubMed Web of Science ®Google Scholar
• Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature. 2005;436:221–6.
   PubMed Web of Science ®Google Scholar
• Bender AM, Collier LS, Rodriguez FJ, Tieu C, Larson JD, Halder C, Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas. Cancer Res. 2010;70:3557–65.
   PubMed Web of Science ®Google Scholar
• Collier LS, Adams DJ, Hackett CS, Bendzick LE, Akagi K, Davies MN, Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Res. 2009;69:8429–37.
   PubMed Web of Science ®Google Scholar
• Felsher DW. MYC inactivation elicits oncogene addiction through both tumor cell-intrinsic and host-dependent mechanisms. Genes Cancer. 2010;1:597–604.
   PubMedGoogle Scholar
• Gustafson WC, Weiss WA. Myc proteins as therapeutic targets. Oncogene. 2010;29:1249–59.
   PubMedGoogle Scholar
• Westermark UK, Wilhelm M, Frenzel A, Henriksson MA. The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol. 2011;21:256–66.
   PubMed Web of Science ®Google Scholar
• Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene. 2003;22:6151–9.
   PubMed Web of Science ®Google Scholar
• Huang MJ, Cheng YC, Liu CR, Lin S, Liu HE. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol. 2006;34:1480–9.
   PubMed Web of Science ®Google Scholar
• Wang H, Hammoudeh DI, Follis AV, Reese BE, Lazo JS, Metallo SJ, Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther. 2007;6:2399–408.
   PubMed Web of Science ®Google Scholar
• Chen J, Willingham T, Margraf LR, Schreiber-Agus N, DePinho RA, Nisen PD. Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells. Nat Med. 1995;1:638–43.
   PubMed Web of Science ®Google Scholar
• Shalaby T, von Bueren AO, Hurlimann ML, Fiaschetti G, Castelletti D, Masayuki T, Disabling c-Myc in childhood medulloblastoma and atypical teratoid/rhabdoid tumor cells by the potent G-quadruplex interactive agent S2T1-6OTD. Mol Cancer Ther. 2010;9:167–79.
   PubMed Web of Science ®Google Scholar
• van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer. 2010;10:301–9.
   PubMed Web of Science ®Google Scholar
• Schlosser I, Holzel M, Murnseer M, Burtscher H, Weidle UH, Eick D. A role for c-Myc in the regulation of ribosomal RNA processing. Nucleic Acids Res. 2003;31:6148–56.
   PubMed Web of Science ®Google Scholar
• Boon K, Caron HN, van Asperen R, Valentijn L, Hermus MC, van Sluis P, N-myc enhances the expression of a large set of genes functioning in ribosome biogenesis and protein synthesis. EMBO J. 2001;20:1383–93.
   PubMed Web of Science ®Google Scholar
• Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, c-Myc regulates transcriptional pause release. Cell. 2010;141:432–45.
   PubMed Web of Science ®Google Scholar
• Knoepfler PS, Zhang XY, Cheng PF, Gafken PR, McMahon SB, Eisenman RN. Myc influences global chromatin structure. EMBO J. 2006;25:2723–34.
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904–17.
   PubMed Web of Science ®Google Scholar
• Marampon F, Ciccarelli C, Zani BM. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer. 2006;5:31.
   PubMed Web of Science ®Google Scholar
• Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell. 2008;14:123–34.
   PubMed Web of Science ®Google Scholar
• Hydbring P, Larsson LG. Tipping the balance: Cdk2 enables Myc to suppress senescence. Cancer Res. 2010;70:6687–91.
   PubMed Web of Science ®Google Scholar
• Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med. 2007;13:820–7.
   PubMed Web of Science ®Google Scholar
• Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992;69:119–28.
   PubMed Web of Science ®Google Scholar
• De Salvo M, Maresca G, D'Agnano I, Marchese R, Stigliano A, Gagliassi R, Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in MGMT expressing glioblastoma cells. Int J Radiat Biol. 2011;87:518–33.
   PubMed Web of Science ®Google Scholar
• Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004;279:2737–46.
   PubMed Web of Science ®Google Scholar
• Peterson RT, Desai BN, Hardwick JS, Schreiber SL. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci USA. 1999;96:4438–42.
   PubMed Web of Science ®Google Scholar
• Chesler L, Schlieve C, Goldenberg DD, Kenney A, Kim G, McMillan A, Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 2006;66:8139–46.
   PubMed Web of Science ®Google Scholar
• Johnsen JI, Segerstrom L, Orrego A, Elfman L, Henriksson M, Kagedal B, Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene. 2008;27:2910–22.
   PubMed Web of Science ®Google Scholar
• Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D, A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006;9:341–9.
   PubMed Web of Science ®Google Scholar
• Baryawno N, Sveinbjornsson B, Eksborg S, Chen CS, Kogner P, Johnsen JI. Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res. 2010;70:266–76.
   PubMed Web of Science ®Google Scholar
• Heine VM, Priller M, Ling J, Rowitch DH, Schuller U. Dexamethasone destabilizes Nmyc to inhibit the growth of hedgehog-associated medulloblastoma. Cancer Res. 2010;70:5220–5.
   PubMedGoogle Scholar
• Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature. 2009;458:438–44.
   PubMed Web of Science ®Google Scholar